Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.66 |
| ▸ | ROR1 | Q01973 | 6/20 | 0.64 |
| ▸ | ABL1 | P00519 | 12/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29506341 | 0.90 | CSF1R (0.67) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL589881 | 0.90 | CSF1R (0.67) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL15096062 | 0.90 | ROR1 (0.67) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL29493472 | 0.89 | CSF1R (0.66) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL22243490 | 0.89 | CSF1R (0.66) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL12652639 | 0.87 | CSF1R (0.72) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL30010219 | 0.87 | CSF1R (0.72) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL15088585 | 0.86 | CSF1R (0.62) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL22580709 | 0.85 | CSF1R (0.61) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL19317721 | 0.83 | ROR1 (0.79) | CSF1RROR1ABL1CYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | ARIAD PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | ARIAD PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | disclosed |
| WO-2014093583-A2 | SYNTHETIC METHODS FOR PREPARING 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE MONO HYDROCHLORIDE, OTHER SALT FORMS OF THIS COMPOUND AND INTERMEDIATES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20140066434-A1 | Methods and Compositions for Treating Parkinson's Disease | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066434-A1 | Methods and Compositions for Treating Parkinson's Disease | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140045826-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | ARIAD PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045826-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | ARIAD PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130178622-A1 | Methods and Compositions for Treating Cancer | ARIAD PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178622-A1 | Methods and Compositions for Treating Cancer | ARIAD PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20120316137-A1 | Methods and Compositions for Treating Cancer | ARIAD PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| WO-2011053938-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | ARIAD PHARMACEUTICALS, INC. (US) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066434-A1 | Methods and Compositions for Treating Parkinson's Disease | PARK7, SNCA, HTT | CSF1R 4420/4885ROR1 3813/4885ABL1 2649/4885 |
| US-20120316137-A1 | Methods and Compositions for Treating Cancer | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, MKI67 | CSF1R 4566/4885ROR1 4639/4885ABL1 140/4885 |
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | BRAF, RAF1, NRAS | CSF1R 2599/4885ROR1 263/4885ABL1 75/4885 |
| US-20140045826-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, MAPT, SNCA | CSF1R 4129/4885ROR1 4480/4885ABL1 4036/4885 |
| US-20130178622-A1 | Methods and Compositions for Treating Cancer | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, MKI67 | CSF1R 4566/4885ROR1 4639/4885ABL1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.